Genmab Gross Profit 2019-2022 | GMAB

Genmab annual/quarterly gross profit history and growth rate from 2019 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Genmab gross profit for the quarter ending March 31, 2022 was $0.320B, a 24.69% increase year-over-year.
  • Genmab gross profit for the twelve months ending March 31, 2022 was $1.413B, a 15.58% decline year-over-year.
  • Genmab annual gross profit for 2021 was $1.349B, a 12.88% decline from 2020.
  • Genmab annual gross profit for 2020 was $1.549B, a 92.58% increase from 2019.
  • Genmab annual gross profit for 2019 was $0.804B, a 67.86% increase from 2018.
Genmab Annual Gross Profit
(Millions of US $)
2021 $1,349
2020 $1,549
2019 $804
2018 $479
Genmab Quarterly Gross Profit
(Millions of US $)
2022-03-31 $320
2021-12-31 $407
2021-09-30 $366
2021-06-30 $320
2021-03-31 $256
2020-12-31 $341
2020-09-30 $271
2020-06-30 $805
2020-03-31 $132
2019-12-31 $443
2019-09-30 $155
2019-06-30 $117
2019-03-31 $90
2018-12-31 $196
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $20.430B $1.349B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00